Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center Study.

ABSTRACT: Survival outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have improved with modern frontline therapies and minimal residual disease (MRD)-guided strategies. As a result, allogeneic hematopoietic cell transplantation (HCT) is increasingly deferred in first remission (CR1) and used in the relapsed setting. However, data on HCT outcomes in second remission (CR2) remain limited in AYAs. We conducted a dual-center retrospective study of AYA patients aged 15-40 years who underwent HCT in CR2 between 2010 and 2022. Among 164 patients, the median age was 25 years; 66% were male and 80% had B-ALL. Frontline therapies included pediatric-inspired (54%) and hyperCVAD-based (33%) regimens. Most received myeloablative conditioning (74%), and 67% were MRD-negative

SUBMITTER: Pasvolsky O 

PROVIDER: S-EPMC12669953 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature